E-MTAB-1567 - Transcriptional profiling of rats with acquired epilepsy treated with two antiinflammatory drugs, VX-765 or Anakinra to study the blockade of IL-1β-mediated signaling in status epilepticus
Released on 10 December 2013, last updated on 21 July 2015
Various studies showed a significant production/release of IL-1 beta following status epilepticus (SE) and during epileptogenesis. We studied the role of this cytokine in the epileptogenic process by blocking its production and downstream effects in vivo in a model of acquired epilepsy following SE induction. We used a pharmacological strategy consisting of the administration of two drugs, namely VX-765 and Anakinra, which selectively block the biosynthesis and the receptor type 1 of this cytokine, respectively.
transcription profiling by array, compound treatment design
Pharmacological blockade of IL-1β/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy. Noe FM, Polascheck N, Frigerio F, Bankstahl M, Ravizza T, Marchini S, Beltrame L, Banderó CR, Löscher W, Vezzani A.